Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative camrelizumab + apatinib in resectable esophageal squamous cell carcinoma
ChiCTR2200065703Phase 4Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Pathological complete response rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2200065703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065703.